

# Hassan Sibai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1931291/publications.pdf>

Version: 2024-02-01

28  
papers

203  
citations

1307366

7  
h-index

1058333

14  
g-index

28  
all docs

28  
docs citations

28  
times ranked

361  
citing authors

#	ARTICLE	IF	CITATIONS
1	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	1.2	56
2	Ponatinib in the therapy of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2016, 9, 923-932.	1.0	36
3	Clinical Utility of Next-Generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. <i>HemaSphere</i> , 2018, 2, e44.	1.2	19
4	A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 156-162.	2.0	17
5	Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. <i>British Journal of Haematology</i> , 2020, 191, 748-754.	1.2	15
6	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 1908-1918.	1.3	10
7	Enasidenib in Combination with Venetoclax in <i>IDH2</i> -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial. <i>Blood</i> , 2021, 138, 1263-1263.	0.6	10
8	Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 774-781.	0.2	6
9	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 600.e1-600.e8.	0.6	5
10	Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib. <i>Leukemia and Lymphoma</i> , 2021, 62, 495-497.	0.6	4
11	Anticoagulation Prophylaxis with Weight-Adjusted Enoxaparin Reduces Rates of Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy. <i>Blood</i> , 2018, 132, 3974-3974.	0.6	4
12	Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort. <i>Leukemia</i> , 2022, 36, 1689-1692.	3.3	4
13	CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study. <i>Blood</i> , 2020, 136, 6-7.	0.6	3
14	Navitoclax plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study. <i>Journal of Clinical Oncology</i> , 2022, 40, 7015-7015.	0.8	3
15	Universal venous thromboembolism policy is effective but may not adequately protect hospitalized cancer patients with larger BMI. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 113-120.	1.0	2
16	Combination treatment with CPX351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature. <i>British Journal of Haematology</i> , 2020, 190, 467-470.	1.2	2
17	Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series. <i>Leukemia and Lymphoma</i> , 2021, 62, 1525-1527.	0.6	2
18	Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS. <i>Blood</i> , 2020, 136, 1-2.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Hemophagocytosis arising during disease progression of chronic myelomonocytic leukemia. International Journal of Laboratory Hematology, 2022, 44, 25-26.	0.7	1
20	Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. Current Oncology, 2021, 28, 128-137.	0.9	1
21	Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era. Blood, 2020, 136, 52-53.	0.6	1
22	Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA. Blood, 2020, 136, 35-36.	0.6	0
23	Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML. Blood, 2020, 136, 15-16.	0.6	0
24	Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measurable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission. Blood, 2020, 136, 36-37.	0.6	0
25	Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation. Blood, 2020, 136, 8-9.	0.6	0
26	Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy. Blood, 2020, 136, 22-22.	0.6	0
27	Prophylaxis with low molecular weight heparin reduces thrombotic events and allows continuation of asparaginase containing regimens during intensification phase. British Journal of Haematology, 2022, , .	1.2	0
28	Osteolytic lesion in polycythemia vera: First report and review of literature. EJHaem, 2022, 3, 526-532.	0.4	0